Calcitonin Salmon NDC 49884-161

NDC codes

FDA NDC Directory

Product NDC (as listed)49884-161Labeler and product segments. Claims need a package NDC.

Product NDC at billing width49884-0161Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
49884-161-11	49884016111	3.7 mL in 1 BOTTLE, GLASS (49884-161-11)Marketed from Jun 8, 2009

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Calcitonin Salmon
Generic name (nonproprietary): calcitonin salmon
Active ingredients: Calcitonin salmon — 200 [iU]/.09mL
Dosage form: Spray, Metered
Route: Nasal
Labeler: Par Health USA, LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 076979
Marketing start: Jun 8, 2009
Listing expires: Dec 31, 2027
Other FDA classes: Calcitonin (Chemical structure)
Identifiers: Product ID 49884-161_0f4b56a3-ce50-41b6-985a-270bf416ffefSPL ID 0f4b56a3-ce50-41b6-985a-270bf416ffefSPL set ID a6eaedb3-5c96-4859-be43-a48c9c818bc7RxCUI 313919UNII 7SFC6U2VI5
Pharmacologic class: Calcitonin

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Nasal products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N449884016111 followed by a unit qualifier and the quantity

Package 49884-0161-11. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jun 29, 2026.

Indications (excerpt from the label)

Calcitonin Salmon Nasal Solution is a calcitonin, indicated for the treatment of postmenopausal osteoporosis in women greater than 5 years postmenopause when alternative treatments are not suitable. Fracture reduction efficacy has not been demonstrated. ( 1.1 ) Limitations of Use: Due to the possible association between malignancy and calcitonin-salmon use, the need for continued therapy should be re-evaluated on a periodic basis. ( 1.2 , 5.4 ) Calcitonin Salmon Nasal Solution has not been shown to increase bone mineral density in early postmenopausal women ( 1.2 ) 1.1 Treatment of Postmenopausal Osteoporosis Calcitonin Salmon Nasal Solution is indicated for the treatment of postmenopausal o…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)